UBS Group AG Has $35.79 Million Stake in STERIS plc (NYSE:STE)

UBS Group AG raised its position in shares of STERIS plc (NYSE:STEFree Report) by 13.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 162,769 shares of the medical equipment provider’s stock after purchasing an additional 18,947 shares during the quarter. UBS Group AG owned 0.16% of STERIS worth $35,785,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its holdings in shares of STERIS by 25.1% during the third quarter. EverSource Wealth Advisors LLC now owns 319 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 64 shares during the period. NBC Securities Inc. purchased a new position in shares of STERIS during the 3rd quarter valued at $50,000. Achmea Investment Management B.V. increased its stake in shares of STERIS by 15.5% in the third quarter. Achmea Investment Management B.V. now owns 9,349 shares of the medical equipment provider’s stock worth $2,052,000 after acquiring an additional 1,256 shares during the last quarter. Ieq Capital LLC raised its holdings in shares of STERIS by 1.1% during the third quarter. Ieq Capital LLC now owns 5,285 shares of the medical equipment provider’s stock worth $1,160,000 after acquiring an additional 55 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in STERIS by 17.2% during the third quarter. Victory Capital Management Inc. now owns 58,719 shares of the medical equipment provider’s stock valued at $12,884,000 after purchasing an additional 8,631 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling at STERIS

In other news, SVP Cary L. Majors sold 2,024 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $232.13, for a total transaction of $469,831.12. Following the completion of the transaction, the senior vice president now directly owns 11,369 shares of the company’s stock, valued at approximately $2,639,085.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Cary L. Majors sold 2,024 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $232.13, for a total transaction of $469,831.12. Following the completion of the transaction, the senior vice president now directly owns 11,369 shares of the company’s stock, valued at approximately $2,639,085.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jacqueline B. Kosecoff sold 4,584 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $231.53, for a total transaction of $1,061,333.52. The disclosure for this sale can be found here. Insiders have sold 7,762 shares of company stock valued at $1,798,477 in the last 90 days. 0.95% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

STE has been the subject of a number of recent research reports. Stephens reaffirmed an “overweight” rating and set a $250.00 price target on shares of STERIS in a research note on Friday, February 9th. KeyCorp initiated coverage on shares of STERIS in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $253.00 target price for the company. Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Friday, May 10th. JMP Securities reiterated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research note on Thursday, May 9th. Finally, TheStreet upgraded STERIS from a “c+” rating to a “b” rating in a report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $241.60.

Check Out Our Latest Analysis on STERIS

STERIS Price Performance

NYSE:STE opened at $229.17 on Monday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.06 and a quick ratio of 2.34. The stock has a market cap of $22.64 billion, a P/E ratio of 59.99 and a beta of 0.81. The company has a fifty day moving average price of $216.92 and a 200 day moving average price of $217.54. STERIS plc has a one year low of $195.47 and a one year high of $254.00.

STERIS (NYSE:STEGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.41 by $0.17. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.41 billion. During the same quarter in the prior year, the business earned $2.30 earnings per share. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. Analysts anticipate that STERIS plc will post 9.12 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 26th. Shareholders of record on Wednesday, June 12th will be paid a dividend of $0.52 per share. The ex-dividend date is Wednesday, June 12th. This represents a $2.08 dividend on an annualized basis and a yield of 0.91%. STERIS’s dividend payout ratio is currently 54.45%.

STERIS Company Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Further Reading

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.